CATX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CATX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Perspective Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil. Perspective Therapeutics's Average Total Inventories for the quarter that ended in Dec. 2023 was $1.01 Mil. Perspective Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for Perspective Therapeutics's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Dec23 | |||||||||||
Inventory Turnover | Get a 7-Day Free Trial | 8.33 | 7.75 | 6.07 | 5.20 | - |
Perspective Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Inventory Turnover | Get a 7-Day Free Trial | 0.90 | 1.04 | 1.00 | 1.11 | - |
Perspective Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as
Inventory Turnover (A: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (A: Dec. 2023 ) | / ( | (Total Inventories (A: Jun. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) |
= | 0 | / ( | (1.396 | + | 0) | / | 1 ) |
= | 0 | / | 1.396 | ||||
= | 0.00 |
Perspective Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover (Q: Dec. 2023 ) | |||||||
= | Cost of Goods Sold | / | Average Total Inventories | ||||
= | Cost of Goods Sold (Q: Dec. 2023 ) | / ( | (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) |
= | 0 | / ( | (1.013 | + | 0) | / | 1 ) |
= | 0 | / | 1.013 | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics (AMEX:CATX) Inventory Turnover Explanation
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Perspective Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2023 ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | 1.013 | / | 0 | * | 365 / 4 | |
= |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Perspective Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | 1.013 | / | -5.239 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Perspective Therapeutics's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Williamson Robert F Iii | director | 140 LASALLE AVENUE, PIEDMONT CA 94610 |
Markus Puhlmann | officer: Chief Medical Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Jonathan Robert Hunt | officer: Chief Financial Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Lori A Woods | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Heidi Henson | director | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
Frank Morich | director | 40 GUEST STREET, BOSTON MA 02135 |
Johan M. Spoor | director, officer: CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Mark John Austin | officer: Controller/Prin Fin&Acct Offic | 350 HILLS ST, STE 106, RICHLAND WA 99354 |
Philip J Vitale | director | 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255 |
Michael W Mccormick | director | 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260 |
William Cavanagh | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Alan Hoffmann | director | 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032 |
Michael Krachon | officer: VP of Sales & Marketing | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Krista Cline | officer: Dir. of Operations, Secretary | 350 HILLS STREET, STE 106, RICHLAND WA 99354 |
Jennifer Streeter | officer: VP of Human Resources | 350 HILLS STREET SUITE 106, RICHLAND WA 99354 |
From GuruFocus
By Marketwired Marketwired • 09-18-2019
By Marketwired Marketwired • 09-10-2018
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 12-03-2018
By GuruFocus Research GuruFocus Editor • 04-12-2021
By PRNewswire PRNewswire • 10-28-2022
By Marketwired Marketwired • 08-13-2019
By Marketwired Marketwired • 05-01-2019
By PRNewswire PRNewswire • 01-07-2021
By Marketwired Marketwired • 10-31-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.